Cantor Fitzgerald Comments on Immatics FY2025 Earnings

Immatics (NASDAQ:IMTX) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Immatics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings per share of ($1.34) for the year. The consensus estimate for Immatics’ current full-year earnings is ($0.79) per share.

IMTX has been the subject of a number of other reports. Bank of America lowered their target price on Immatics from $16.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, November 19th. Piper Sandler initiated coverage on shares of Immatics in a research report on Monday, October 7th. They set an “overweight” rating and a $19.00 target price on the stock. Finally, The Goldman Sachs Group raised shares of Immatics to a “strong-buy” rating in a research note on Monday, November 25th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Immatics presently has an average rating of “Buy” and an average price target of $16.67.

Immatics Stock Performance

NASDAQ:IMTX opened at $5.57 on Wednesday. The company has a market capitalization of $664.84 million, a PE ratio of -8.44 and a beta of 0.77. Immatics has a fifty-two week low of $5.27 and a fifty-two week high of $13.77. The company has a 50 day simple moving average of $7.16 and a two-hundred day simple moving average of $9.70.

Institutional Investors Weigh In On Immatics

A number of hedge funds have recently modified their holdings of the stock. Vestal Point Capital LP boosted its stake in Immatics by 36.4% in the 3rd quarter. Vestal Point Capital LP now owns 3,750,000 shares of the company’s stock worth $42,788,000 after purchasing an additional 1,000,000 shares during the period. Frazier Life Sciences Management L.P. bought a new position in shares of Immatics in the second quarter valued at approximately $13,392,000. abrdn plc purchased a new position in Immatics during the third quarter valued at approximately $2,657,000. Wellington Management Group LLP increased its holdings in Immatics by 1.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,681,183 shares of the company’s stock worth $110,462,000 after acquiring an additional 144,549 shares during the period. Finally, Perceptive Advisors LLC lifted its stake in Immatics by 76.5% in the 2nd quarter. Perceptive Advisors LLC now owns 8,086,159 shares of the company’s stock worth $93,961,000 after purchasing an additional 3,503,750 shares in the last quarter. Institutional investors own 64.41% of the company’s stock.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.